A standardised model for stool banking for faecal micro
consensus report from a multidisciplinary UEG workin

United European Gastroenterology Journal

9, 229-247

DOI: 10.1177/2050640620967898

Citation Report

#	Article	IF	Citations
1	Fidaxomicin. , 2021, , .		0
2	Ten-Year Follow-Up of Patients Treated with Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection from a Randomized Controlled Trial and Review of the Literature. Microorganisms, 2021, 9, 548.	3.6	9
3	Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to Clostridioides difficile Infections into the Local Clinical Practice. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 147-163.	0.9	0
4	Faecal microbiota transplants: Why do we not consider them as Advanced Therapy Medicinal Products?. United European Gastroenterology Journal, 2021, 9, 519-520.	3.8	0
5	Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21st century. World Journal of Gastroenterology, 2021, 27, 2921-2943.	3.3	13
6	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. Lancet Regional Health - Europe, The, 2021, 9, 100181.	5.6	43
8	Fecal Microbiota Transplantation Influences Procarcinogenic Escherichia coli in Recipient Recurrent Clostridioides difficile Patients. Gastroenterology, 2021, 161, 1218-1228.e5.	1.3	18
9	Systematic review with meta-analysis: encapsulated faecal microbiota transplantation â€“ evidence for clinical efficacy. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110410.	3.2	18
10	Stools' donor recruitment, a challenge in pandemic times. United European Gastroenterology Journal, 2021, 9, 993-994.	3.8	0
11	How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection. Clinical Microbiology and Infection, 2022, 28, 502-512.	6.0	6
12	Clinical Parasitology and Parasitome Maps as Old and New Tools to Improve Clinical Microbiomics. Pathogens, 2021, 10, 1550.	2.8	4
13	The emerging potential of microbiome transplantation on human health interventions. Computational and Structural Biotechnology Journal, 2022, 20, 615-627.	4.1	14
14	Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. Trials, 2022, 23, 173.	1.6	7
15	Fecal Microbiota Transplantation for Refractory Clostridioides Difficile Infection Is Effective and Well Tolerated Even in Very Old Subjects: A Real-Life Study. Journal of Nutrition, Health and Aging, 2022, 26, 290-296.	3.3	2
16	How to prepare stool banks for an appropriate response to the ongoing COVID-19 pandemic: Experiences in the Netherlands and a retrospective comparative cohort study for faecal microbiota transplantation. PLoS ONE, 2022, 17, e0265426.	2.5	1
17	Multi-Donor Fecal Microbial Transplantation for Critically Ill Patients: Rationale and Standard Operating Procedure. Future Pharmacology, 2022, 2, 55-63.	1.8	2
18	The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases. Gut Microbes, 2022, 14, 2038856.	9.8	16
19	The Regulatory Approach for Faecal Microbiota Transplantation as Treatment for Clostridioides difficile Infection in Italy. Antibiotics, 2022, 11, 480.	3.7	5

#	Article	IF	Citations
21	Adverse events of intestinal microbiota transplantation in randomized controlled trials: a systematic review and meta-analysis. Gut Pathogens, 2022, 14, .	3.4	4
22	Design and manufacture of a lyophilised faecal microbiota capsule formulation to GMP standards. Journal of Controlled Release, 2022, 350, 324-331.	9.9	5
24	Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice. Lancet Haematology,the, 2022, 9, e776-e785.	4.6	8
25	Gut microbiome dysbiosis in inflammatory bowel disease. Progress in Molecular Biology and Translational Science, 2022, , 179-204.	1.7	5
26	Special Issue on the â€œRegulation and Physiopathology of the Gut Barrierâ€• International Journal of Molecular Sciences, 2022, 23, 10638.	4.1	1
27	Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 1083-1091.	8.1	37
28	Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel. The Lancet Gastroenterology and Hepatology, 2022, 7, 979-980.	8.1	8
29	Total Gastrointestinal Flora Transplantation in the Treatment of Leaky Gut Syndrome and Flora Loss. Cureus, 2022, , .	0.5	1
30	Faecal microbiota transplantation for recurrent C. difficile infections: challenges and improvement opportunities for clinical practice and healthcare systems. Alimentary Pharmacology and Therapeutics, 2023, 57, 549-564.	3.7	4
31	Fecal microbiota transplantation in childhood: past, present, and future. World Journal of Pediatrics, 2023, 19, 813-822.	1.8	3
32	From fecal microbiota transplantation toward next-generation beneficial microbes: The case of Anaerobutyricum soehngenii. Frontiers in Medicine, 0, 9, .	2.6	4
33	ESPEN guideline on Clinical Nutrition in inflammatory bowel disease. Clinical Nutrition, 2023, 42, 352-379.	5.0	46
34	Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial. BMC Cancer, 2022, 22, .	2.6	6
36	Is there a role for microbiome-based approach in common variable immunodeficiency?. Clinical and Experimental Medicine, 2023, 23, 1981-1998.	3.6	2
37	Risk of Helicobacter pylori transmission by faecal microbiota transplantation via oral capsules. Clinical Microbiology and Infection, 2023, 29, 799.e1-799.e4.	6.0	1
38	Stool donor screening within a Therapeutic Goods Administration compliant donor screening program for fecal microbiota transplantation. JGH Open, 2023, 7, 172-177.	1.6	2
39	Emerging roles of the gut microbiota in cancer immunotherapy. Frontiers in Immunology, 0, 14, .	4.8	5
40	Beyond faecal microbiota transplantation, the non-negligible role of faecal virome or bacteriophage transplantation. Journal of Microbiology, Immunology and Infection, 2023, 56, 893-908.	3.1	4

#	Article	IF	Citations
41	Microbiome analysis and fecal microbiota transfer in pediatric gastroenterologyÂâ€"Âa structured online survey in German-speaking countries. International Journal of Colorectal Disease, 2023, 38, .	2.2	0
42	Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent Clostridioides difficile infection in patients with inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2023, 16, 175628482311562.	3.2	4
43	Fecal microbiota transfer to treat ulcerative colitis: Medical and legal challenges. , 0, 2, .		2
44	The Microbiome and Its Impact on Allogeneic Hematopoietic Cell Transplantation. Cancer Journal (Sudbury, Mass), 2023, 29, 75-83.	2.0	0
45	Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2023, 24, 6123.	4.1	7
46	Is Autologous Fecal Microbiota Transfer after Exclusive Enteral Nutrition in Pediatric Crohnâ€™s Disease Patients Rational and Feasible? Data from a Feasibility Test. Nutrients, 2023, 15, 1742.	4.1	1
47	Dry alginate beads for fecal microbiota transplantation: From model strains to fecal samples. International Journal of Pharmaceutics, 2023, 639, 122961.	5.2	0
48	Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with concurrent ulcerative colitis. Journal of Autoimmunity, 2023, 141, 103033.	6.5	1
49	The role of faecal microbiota transplantation in chronic noncommunicable disorders. Journal of Autoimmunity, 2023, 141, 103034.	6.5	3
50	Gutâ€"liver axis: barriers and functional circuits. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 447-461.	17.8	26
51	Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: A systematic review and meta-analysis. Journal of Autoimmunity, 2023, 141, 103036.	6.5	2
52	Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota. Nutrients, 2023, 15, 2211.	4.1	48
53	Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. World Journal of Gastroenterology, 0, 29, 3185-3202.	3.3	6
55	Fecal microbiota transplantation for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Immunology, 0, 14, .	4.8	7
56	Safety of fecal microbiota, live-jslm (REBYOTA^{â„¢}) in individuals with recurrentClostridioides difficileinfection: data from five prospective clinical trials. Therapeutic Advances in Gastroenterology, 2023, 16, .	3.2	18
58	Donor, patient age and exposure to antibiotics are associated with the outcome of faecal microbiota transplantation for recurrent Clostridioides difficile infection: A prospective cohort study. Alimentary Pharmacology and Therapeutics, 2023, 58, 503-515.	3.7	2
59	Anaerobic Feces Processing for Fecal Microbiota Transplantation Improves Viability of Obligate Anaerobes. Microorganisms, 2023, 11, 2238.	3.6	2
60	Swiss expert opinion: current approaches in faecal microbiota transplantation in daily practice. Swiss Medical Weekly, 2023, 153, 40100.	1.6	0

#	Article	IF	Citations
61	Editorial: Continuous monitoring to improve outcome of treatmentâ€"the next step towards safe and effective faecal microbiota transplantation. Alimentary Pharmacology and Therapeutics, 2023, 58, 946-947.	3.7	1
62	Fecal microbiota transplantationâ€"could stool donorsâ€™ and receptorsâ€™ diet be the key to future success?. , 0, 2, .		0
63	Development of a Protocol for Anaerobic Preparation and Banking of Fecal Microbiota Transplantation Material: Evaluation of Bacterial Richness in the Cultivated Fraction. Microorganisms, 2023, 11, 2901.	3.6	0
65	Microbiota-Based Therapeutics as New Standard-of-Care Treatment for Recurrent <i>Clostridioides difficile</i> Infection. Visceral Medicine, 2024, 40, 82-91.	1.3	0